vs

Side-by-side financial comparison of ARBOR REALTY TRUST INC (ABR) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

ARBOR REALTY TRUST INC is the larger business by last-quarter revenue ($133.4M vs $85.1M, roughly 1.6× 4D Molecular Therapeutics, Inc.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -12.1%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -8.9%).

Arbor Realty Trust Inc. is a U.S.-headquartered specialized real estate investment trust (REIT). It primarily provides structured financing solutions for multifamily residential and commercial real estate projects, including bridge loans, agency lending, and mezzanine financing. Its core market covers the U.S. real estate sector, serving property owners, developers and real estate investors nationwide.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

ABR vs FDMT — Head-to-Head

Bigger by revenue
ABR
ABR
1.6× larger
ABR
$133.4M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508912.1% gap
FDMT
8508900.0%
-12.1%
ABR
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-8.9%
ABR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABR
ABR
FDMT
FDMT
Revenue
$133.4M
$85.1M
Net Profit
$19.4M
Gross Margin
Operating Margin
17.3%
Net Margin
22.8%
Revenue YoY
-12.1%
8508900.0%
Net Profit YoY
139.1%
EPS (diluted)
$0.08
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABR
ABR
FDMT
FDMT
Q4 25
$133.4M
$85.1M
Q3 25
$112.4M
$90.0K
Q2 25
$130.4M
$15.0K
Q1 25
$134.2M
$14.0K
Q4 24
$151.7M
$1.0K
Q3 24
$156.7M
$3.0K
Q2 24
$153.1M
$5.0K
Q1 24
$160.7M
$28.0K
Net Profit
ABR
ABR
FDMT
FDMT
Q4 25
$19.4M
Q3 25
$52.0M
$-56.9M
Q2 25
$36.3M
$-54.7M
Q1 25
$43.4M
$-48.0M
Q4 24
Q3 24
$73.5M
$-43.8M
Q2 24
$61.8M
$-35.0M
Q1 24
$73.2M
$-32.4M
Operating Margin
ABR
ABR
FDMT
FDMT
Q4 25
17.3%
Q3 25
-67983.3%
Q2 25
-396373.3%
Q1 25
-383007.1%
Q4 24
Q3 24
-1704400.0%
Q2 24
-849120.0%
Q1 24
46.9%
-136200.0%
Net Margin
ABR
ABR
FDMT
FDMT
Q4 25
22.8%
Q3 25
46.3%
-63195.6%
Q2 25
27.8%
-364386.7%
Q1 25
32.3%
-342657.1%
Q4 24
Q3 24
46.9%
-1461433.3%
Q2 24
40.4%
-699060.0%
Q1 24
45.6%
-115717.9%
EPS (diluted)
ABR
ABR
FDMT
FDMT
Q4 25
$0.08
$0.43
Q3 25
$0.20
$-1.01
Q2 25
$0.12
$-0.98
Q1 25
$0.16
$-0.86
Q4 24
$0.31
Q3 24
$0.31
$-0.79
Q2 24
$0.25
$-0.63
Q1 24
$0.31
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABR
ABR
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$482.9M
$402.7M
Total DebtLower is stronger
$11.1B
Stockholders' EquityBook value
$3.0B
$505.7M
Total Assets
$14.5B
$566.7M
Debt / EquityLower = less leverage
3.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABR
ABR
FDMT
FDMT
Q4 25
$482.9M
$402.7M
Q3 25
$423.4M
$305.1M
Q2 25
$255.7M
$293.2M
Q1 25
$308.8M
$321.4M
Q4 24
$503.8M
$424.9M
Q3 24
$687.5M
$501.9M
Q2 24
$737.5M
$541.9M
Q1 24
$908.0M
$525.9M
Total Debt
ABR
ABR
FDMT
FDMT
Q4 25
$11.1B
Q3 25
$10.4B
Q2 25
$10.1B
Q1 25
$9.9B
Q4 24
$10.0B
Q3 24
$10.3B
Q2 24
$10.6B
Q1 24
$11.4B
Stockholders' Equity
ABR
ABR
FDMT
FDMT
Q4 25
$3.0B
$505.7M
Q3 25
$3.0B
$369.0M
Q2 25
$3.0B
$420.9M
Q1 25
$3.0B
$469.7M
Q4 24
$3.0B
$510.6M
Q3 24
$3.0B
$552.9M
Q2 24
$3.1B
$588.3M
Q1 24
$3.1B
$600.6M
Total Assets
ABR
ABR
FDMT
FDMT
Q4 25
$14.5B
$566.7M
Q3 25
$13.9B
$424.0M
Q2 25
$13.6B
$473.6M
Q1 25
$13.4B
$515.7M
Q4 24
$13.5B
$560.4M
Q3 24
$13.9B
$604.0M
Q2 24
$14.2B
$620.1M
Q1 24
$15.1B
$629.9M
Debt / Equity
ABR
ABR
FDMT
FDMT
Q4 25
3.75×
Q3 25
3.47×
Q2 25
3.40×
Q1 25
3.29×
Q4 24
3.29×
Q3 24
3.40×
Q2 24
3.47×
Q1 24
3.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABR
ABR
FDMT
FDMT
Operating Cash FlowLast quarter
$372.4M
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABR
ABR
FDMT
FDMT
Q4 25
$372.4M
$28.6M
Q3 25
$178.7M
$-46.5M
Q2 25
$60.0M
$-43.4M
Q1 25
$150.5M
$-47.8M
Q4 24
$461.5M
$-134.6M
Q3 24
$85.0M
$-29.4M
Q2 24
$69.9M
$-30.2M
Q1 24
$260.0M
$-29.1M
Free Cash Flow
ABR
ABR
FDMT
FDMT
Q4 25
$28.5M
Q3 25
$-46.6M
Q2 25
$-43.4M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$-31.2M
Q2 24
$-30.6M
Q1 24
$-29.8M
FCF Margin
ABR
ABR
FDMT
FDMT
Q4 25
33.5%
Q3 25
-51765.6%
Q2 25
-289620.0%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
Q2 24
-611840.0%
Q1 24
-106421.4%
Capex Intensity
ABR
ABR
FDMT
FDMT
Q4 25
0.1%
Q3 25
101.1%
Q2 25
440.0%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
59266.7%
Q2 24
6980.0%
Q1 24
2535.7%
Cash Conversion
ABR
ABR
FDMT
FDMT
Q4 25
1.47×
Q3 25
3.44×
Q2 25
1.65×
Q1 25
3.47×
Q4 24
Q3 24
1.16×
Q2 24
1.13×
Q1 24
3.55×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons